冠心病心血瘀阻证与血液纤溶酶原激活物抑制剂-1基因的关系

目的：探讨冠心病心血瘀阻证与纤溶酶原激活物抑制剂－1（PAI－1）基因启动子区4G／5G多态性的关系。方法：把36例冠心病患者分为两组：心血瘀阻证组与非心血瘀阻证组，另外收集16例健康者作为正常对照组。分别测定各组病例的PAI－1启动子区4G／5G基因型，同时测定血浆PAI－1活性、血脂、血糖及凝血功能等指标。结果与结论：心血瘀阻证患者4G／4G基因型（50．00％）高于正常对照组（31．25％）及非心血瘀阻证组（25．00％），提示PAI－1基因4G／4G多态性可能与冠心病心血瘀阻证相关，结论有待于进一步扩大样本量证实。还发现血浆PAI－1活性、纤维蛋白原与PAI－1基因4G／5G多态性相关，提示PAI－1活性升高与纤维蛋白原增高是PAI－1启动子区4G／5G基因型易致冠心病心血瘀阻证的可能机制。

Relationship Between Plasminogen Activator Inhibitor-1 Gene and Coronary Heart Disease with Blood-stagnation Syndrome

Objective] To explore the relationship between 4G/5G genetic polymorphism in the promoter of plasminogen activator inhibitor - 1 (PAI - 1) and coronary heart disease with blood - stagnation syndrome. Methods ] Thirty - six cases of coronary heart disease were randomly allocated to blood - stagnation syndrome group (Group B) and non - blood - stagnation syndrome group ( Group C) and sixteen healthy volunteers served as control group (Group A). PAI - 1 pro-motor 4G/5G types were detected. Plasma PAI - 1 activity, levels of blood lipids and blood glucose and the blood coagulation function were, also measured. Results & Conclusion] PAI - 1 4G/4G genotype occurred in blood - stagnation syndrome group (50.00%), non-blood- stagnation syndrome group (25.00%) and control group (31.25%) with no significant difference, which indicates that the polymorphism of 4G/5G may be related to the blood - stagnation syndrome in coronary heart disease. The plasma PAI - 1 activity and fibrinogen level were correlated with 4G/5G genetic polymorphism , suggesting that the increase of PAI - 1 activity and fibrinogen level may be the risk factor of PAI - 1 4G/4G genotype inducing coronary heart disease with blood - stagnation syndrome.